特应性皮炎的局部和传统全身治疗：它们过时了吗？
Topical and Conventional Systemic Treatments in Atopic Dermatitis: Have They Gone Out of Fashion?
作者信息
Calabrese Giulia, Licata Gaetano, Gambardella Alessio, De Rosa Alina, Alfano Roberto, Argenziano Giuseppe
机构信息
Dermatology Unit, Department of Mental and Physical Health and Preventive Medicine, University of Campania Luigi Vanvitelli, Naples, Italy.
Department of Anesthesiology Surgery and Emergency, University of Campania Luigi Vanvitelli, Naples, Italy.
出版信息
Dermatol Pract Concept. 2022 Jan 1;12(1):e2022155. doi: 10.5826/dpc.1201a155. eCollection 2022 Feb.
Abstract
Atopic dermatitis is a Th2 disease, due to relapse of IL-4 and IL-13 by Th2 cells. Despite the approval by FDA of dupilumab, the first monoclonal antibody for the severe forms, traditional drugs remain a milestone for the treatment of this dermatosis. Dermatologists need a good knowledge of all therapies for an integrated and personalized management of patients.
摘要
特应性皮炎是一种Th2型疾病，由Th2细胞释放白细胞介素-4和白细胞介素-13导致病情复发。尽管美国食品药品监督管理局（FDA）已批准度普利尤单抗（第一种用于治疗重度特应性皮炎的单克隆抗体），但传统药物仍是治疗这种皮肤病的重要手段。皮肤科医生需要全面了解所有治疗方法，以便对患者进行综合、个性化管理。
相似文献
1
Topical and Conventional Systemic Treatments in Atopic Dermatitis: Have They Gone Out of Fashion?特应性皮炎的局部和传统全身治疗：它们过时了吗？
Dermatol Pract Concept. 2022 Jan 1;12(1):e2022155. doi: 10.5826/dpc.1201a155. eCollection 2022 Feb.
2
Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial.度普利尤单抗联合外用皮质类固醇治疗中重度特应性皮炎的长期管理（LIBERTY AD CHRONOS）：一项为期 1 年、随机、双盲、安慰剂对照、3 期临床试验。
Lancet. 2017 Jun 10;389(10086):2287-2303. doi: 10.1016/S0140-6736(17)31191-1. Epub 2017 May 4.
3
Dupilumab: A review of its use in the treatment of atopic dermatitis.度普利尤单抗：治疗特应性皮炎的研究进展。
J Am Acad Dermatol. 2018 Mar;78(3 Suppl 1):S28-S36. doi: 10.1016/j.jaad.2017.12.022.
4
Dupilumab for treatment of atopic dermatitis.度普利尤单抗治疗特应性皮炎。
Expert Rev Clin Pharmacol. 2018 May;11(5):467-474. doi: 10.1080/17512433.2018.1449642. Epub 2018 Mar 20.
5
Dupilumab in the treatment of moderate-to-severe atopic dermatitis.度普利尤单抗治疗中重度特应性皮炎
Expert Rev Clin Immunol. 2017 Apr;13(4):301-310. doi: 10.1080/1744666X.2017.1292134. Epub 2017 Feb 15.
6
Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ).度普利尤单抗联合外用皮质类固醇治疗对环孢素 A 应答不足或不耐受或当这种治疗在医学上不建议时的中重度特应性皮炎成人患者：一项安慰剂对照、随机 III 期临床试验（LIBERTY AD CAFÉ）。
Br J Dermatol. 2018 May;178(5):1083-1101. doi: 10.1111/bjd.16156. Epub 2018 Mar 25.
7
Dupilumab for the treatment of adolescents with atopic dermatitis.度普利尤单抗治疗青少年特应性皮炎。
Expert Rev Clin Immunol. 2020 Jul;16(7):641-650. doi: 10.1080/1744666X.2020.1801420. Epub 2020 Aug 13.
8
Current and Future Monoclonal Antibodies in the Treatment of Atopic Dermatitis.当前和未来用于治疗特应性皮炎的单克隆抗体。
Clin Rev Allergy Immunol. 2020 Oct;59(2):208-219. doi: 10.1007/s12016-020-08802-9.
9
Management of dupilumab-associated ocular surface diseases in atopic dermatitis patients.特应性皮炎患者度普利尤单抗相关眼表疾病的管理。
Swiss Med Wkly. 2021 Aug 20;151:w30020. doi: 10.4414/SMW.2021.w30020.
10
Efficacy of Dupilumab in two patients with severe and recalcitrant atopic dermatitis previously treated with extracorporeal photopheresis.度普利尤单抗在两名曾接受体外光化学疗法治疗的重度顽固性特应性皮炎患者中的疗效。
Dermatol Ther. 2020 May;33(3):e13284. doi: 10.1111/dth.13284. Epub 2020 Mar 2.
引用本文的文献
1
Efficacy and Safety of Zabedosertib, an Interleukin-1 Receptor-Associated Kinase 4 Inhibitor, in Patients with Moderate-to-Severe Atopic Dermatitis: A Phase II Randomized Study.白细胞介素-1受体相关激酶4抑制剂扎贝多西替布治疗中重度特应性皮炎患者的疗效与安全性：一项II期随机研究
Dermatol Ther (Heidelb). 2025 Sep 4. doi: 10.1007/s13555-025-01505-z.
2
Atopic Dermatitis Management: from Conventional Therapies to Biomarker-Driven Treatment Approaches.特应性皮炎的管理：从传统疗法到生物标志物驱动的治疗方法。
Biomol Ther (Seoul). 2025 Sep 1;33(5):813-829. doi: 10.4062/biomolther.2025.081. Epub 2025 Aug 19.
3
Development and optimization of a novel nanocarrier SabiWhite-loaded ethosomal gel for targeted skin inflammation complicated by multidrug-resistant pathogens.一种新型载有SabiWhite的乙醇胺脂质体凝胶用于治疗由多重耐药病原体引起的靶向性皮肤炎症的研发与优化
Front Cell Infect Microbiol. 2025 Jul 22;15:1640799. doi: 10.3389/fcimb.2025.1640799. eCollection 2025.
4
Cure for the itch: current clinical standards and therapies in allergic eczema.瘙痒症的治疗：过敏性湿疹的当前临床标准与疗法
Front Allergy. 2025 Apr 3;6:1569292. doi: 10.3389/falgy.2025.1569292. eCollection 2025.
5
Atopic dermatitis: a comprehensive updated review of this intriguing disease with futuristic insights.特应性皮炎：对这种有趣疾病的全面更新综述及未来展望。
Inflammopharmacology. 2025 Mar;33(3):1161-1187. doi: 10.1007/s10787-025-01642-z. Epub 2025 Feb 7.
6
Efficacy of dupilumab with concomitant topical calcineurin inhibitors treatment for preschool children with atopic dermatitis: a retrospective cohort study.度普利尤单抗联合外用钙调神经磷酸酶抑制剂治疗学龄前儿童特应性皮炎的疗效：一项回顾性队列研究
Ann Med. 2025 Dec;57(1):2449589. doi: 10.1080/07853890.2025.2449589. Epub 2025 Jan 6.
7
Exploring the Complexities of Atopic Dermatitis: Pathophysiological Mechanisms and Therapeutic Approaches.探索特应性皮炎的复杂性：病理生理机制与治疗方法
J Biotechnol Biomed. 2024;7(3):314-328. doi: 10.26502/jbb.2642-91280155. Epub 2024 Jul 17.
8
Unraveling the skin; a comprehensive review of atopic dermatitis, current understanding, and approaches.揭开皮肤之谜：特应性皮炎的全面综述、现有认识和方法。
Front Immunol. 2024 Mar 4;15:1361005. doi: 10.3389/fimmu.2024.1361005. eCollection 2024.
9
A comparative randomized clinical trial evaluating the efficacy and safety of tacrolimus versus hydrocortisone as a topical treatment of atopic dermatitis in children.一项比较随机临床试验，评估他克莫司与氢化可的松作为儿童特应性皮炎局部治疗药物的疗效和安全性。
Front Pharmacol. 2023 Sep 20;14:1202325. doi: 10.3389/fphar.2023.1202325. eCollection 2023.
本文引用的文献
1
Dupilumab and conjunctivitis: a case series of twenty patients.度普利尤单抗与结膜炎：20例患者的病例系列
J Eur Acad Dermatol Venereol. 2021 Sep;35(9):e612-e614. doi: 10.1111/jdv.17210. Epub 2021 Jun 11.
2
Successful Combination of Systemic Agents for the Treatment of Atopic Dermatitis Resistant to Dupilumab Therapy.成功联合全身用药物治疗对度普利尤单抗治疗抵抗的特应性皮炎。
Dermatology. 2021;237(4):535-541. doi: 10.1159/000512890. Epub 2021 Jan 21.
3
Dupilumab probably reduces transepidermal water loss but does not increase stratum corneum hydration in atopic dermatitis.度普利尤单抗可能会减少特应性皮炎患者的经表皮水分流失，但不会增加角质层水合作用。
J Dermatol. 2021 Feb;48(2):e74-e75. doi: 10.1111/1346-8138.15638. Epub 2020 Oct 9.
4
A Practical Approach to Recalcitrant Face and Neck Dermatitis in Atopic Dermatitis.特应性皮炎中难治性面颈部皮炎的实用处理方法。
Dermatitis. 2020 May-Jun;31(3):169-177. doi: 10.1097/DER.0000000000000590.
5
Dupilumab improves clinical manifestations, symptoms, and quality of life in adult patients with chronic nodular prurigo.度普利尤单抗可改善慢性结节性痒疹成年患者的临床表现、症状和生活质量。
J Am Acad Dermatol. 2020 Jul;83(1):39-45. doi: 10.1016/j.jaad.2020.03.049. Epub 2020 Mar 27.
6
Dupilumab treatment results in early and sustained improvements in itch in adolescents and adults with moderate to severe atopic dermatitis: Analysis of the randomized phase 3 studies SOLO 1 and SOLO 2, AD ADOL, and CHRONOS.度普利尤单抗治疗可使中度至重度特应性皮炎的青少年和成人瘙痒症状得到早期且持续的改善：随机3期研究SOLO 1、SOLO 2、AD ADOL和CHRONOS的分析。
J Am Acad Dermatol. 2020 Jun;82(6):1328-1336. doi: 10.1016/j.jaad.2020.02.060. Epub 2020 Mar 3.
7
Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in adult cohort: a real-life Italian tertiary centre experience.度普利尤单抗治疗成人特应性皮炎的有效性和安全性：意大利一家三级中心的真实世界经验
J Eur Acad Dermatol Venereol. 2020 Aug;34(8):e380-e383. doi: 10.1111/jdv.16219. Epub 2020 May 22.
8
Risk Factors for Dupilumab-Associated Conjunctivitis in Patients With Atopic Dermatitis.特应性皮炎患者接受度普利尤单抗治疗相关结膜炎的风险因素。
JAMA Dermatol. 2018 Oct 1;154(10):1208-1211. doi: 10.1001/jamadermatol.2018.2690.
9
Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial.度普利尤单抗联合外用皮质类固醇治疗中重度特应性皮炎的长期管理（LIBERTY AD CHRONOS）：一项为期 1 年、随机、双盲、安慰剂对照、3 期临床试验。
Lancet. 2017 Jun 10;389(10086):2287-2303. doi: 10.1016/S0140-6736(17)31191-1. Epub 2017 May 4.
10
Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies.特应性皮炎管理指南：第 2 节。特应性皮炎的局部治疗管理和治疗。
J Am Acad Dermatol. 2014 Jul;71(1):116-32. doi: 10.1016/j.jaad.2014.03.023. Epub 2014 May 9.
Zotero 插件